Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis.

Trial Profile

An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mercaptamine (Primary)
  • Indications Cystic fibrosis
  • Focus First in man; Pharmacokinetics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Apr 2017 This trial has been discontinued in UK (End date:2015-03-06) as per European Clinical Trials Database record.
    • 24 Jun 2016 According to a NovaBiotics media release, data this trial was presented at the ASM Microbe conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top